Updated:
AgeX Therapeutics
AgeX Therapeutics is a biotechnology company founded in 2017 in Alameda, California. It develops and commercializes therapeutics targeting human aging.
AgeX Therapeutics
AgeX Therapeutics is a biotechnology company founded in 2017 in Alameda, California. It develops and commercializes therapeutics targeting human aging. The company generates pluripotent stem cell-derived young cells for potential use in degenerative diseases of aging.
General information
Firm type
Asset Manager
Year founded
2017
Location
Region
North America
Country
United States
City
Alameda
Corporate office
Alameda, CA, United States
Principals
Michael D. West
Founder and CEO
Sector focus
Frequently asked questions
How is AgeX related to BioTime and Geron?
Michael West founded Geron Corporation in 1990 and later co-founded BioTime in 2001. AgeX was spun out of BioTime in 2017 as a subsidiary focused specifically on the therapeutic application of pluripotent stem cells and telomerase biology. In 2019, BioTime distributed AgeX shares to its shareholders, fully separating the companies. BioTime later rebranded to Lineage Cell Therapeutics.
What is AgeX's core scientific platform?
AgeX operates two platforms: PureStem, which produces clonal embryonic progenitor cell lines to regenerate young tissue, and UniverCyte, which uses human leukocyte antigen engineering to create universal donor stem cells. Both aim at diseases of aging, not cosmetic longevity or wellness services.
How does AgeX Therapeutics fund its operations?
AgeX funds operations through public equity raises, warrant exercises, and occasional grant or collaboration revenue. As a micro-cap public company, it does not charge management fees or accept LP commitments, unlike a venture fund or institutional asset manager. The 2023 merger with Serina Therapeutics brought a second platform and additional research assets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: